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Abstract
Background: HPV-16 modifies the overall survival (OS) of patients with oropharyngeal cancer (OPSCC). HPV-16 has
been established as risk factor for OPSCC, but HPV-16 infection may also reside in the larynx and oral cavity.
We evaluated HPV-16 status on OS of Head and Neck Squamous Cell Carcinoma (HNSCC) patients.
Methods: HPV-16 infection was confirmed by amplification of E6 and E7 viral oncogenes through PCR assay
and E6 IHC in 185 HNSCC samples. Associations between HPV-16 status and clinicopathological parameters
were performed using Fisher’s exact test and x2. Survival analysis was completed using Kaplan-Meier estimator
and multivariate Cox regression analysis.
Results: OS of HPV-16 positive patients was longer compared to HPV-16 negative patients (P = 0.002). HPV-16
positive tumors of the larynx (LSCC) and pharynx (PSCC) showed improved OS compared to HPV-16 negative
tumors. Also, HPV-16 positive patients exposed to radiotherapy presented a better survival.
Conclusions: HPV-16 status has a positive prognostic value in HNSCC. Addition of HPV-16 status to the TNM
staging can provide better assessment in prognosis and guide treatment for HNSCC patients.
Keywords: Head and neck squamous cell carcinoma, Human Papillomavirus (HPV), Overall Survival (OS), TNM, Biomarker
Background
HNSCC is the seventh most common type of cancer di-
agnosed, and it is ranked as the eighth cause of cancer
death worldwide [1, 2]. This cancer includes tumors
from the oral cavity (OSCC) (ICD-10-C14.8), pharynx
(PSCC) (ICD-10-C14.0), larynx (LSCC) (ICD-10-C32.9),
and the paranasal sinuses (ICD-10-C31.9) [3]. HNSCC is
predominantly diagnosed in patients over 60 years old;
however, a growing number of HNSCC patients are be-
ing diagnosed at younger ages [4]. Historically, HNSCC
has been more frequently diagnosed in men, with a
male–female ratio of about 4:1. However, this ratio is
rapidly changing because more women are exposing
themselves to tobacco and alcohol [5]. The overall-5-
year survival (OS) for HNSCC patients is 65.9 %, for all
HNSCC sites and stages [6], with a median survival of
2.5 years after treatment.
In the United States, Puerto Rican Hispanics, African-
Americans, and economically disadvantaged Whites are at
greater risk of developing HNSCC. The incidence of
HNSCC in Puerto Ricans is 2.5 higher than Hispanics in
the US [7]. The incidence of OSCC or PSCC is approxi-
mately 72 % higher in Puerto Ricans than in US Hispanics.
Similarly, the incidence rate of LSCC is 51 % higher than
among Hispanics living in the Unites States [7].
The etiology of HNSCC involves a variety of toxic, en-
vironmental, and viral agents [5]. Studies have established
that smoking and alcohol consumption are the major risk
factors for the development of HNSCC [8–10]. Currently,
human papillomavirus (HPV) infection has also been rec-
ognized as a risk factor for HNSCC, particularly for
OPSCC [11–13]. There are more than 180 types of HPVs
described, of which 30 types are considered high risk, in-
cluding HPV-16 and HPV-18 [14, 15]. The malignant
transformation of HPV integration is mediated by HPV
oncoproteins E6 and E7 [14]. HPV-16 E6 protein has been
associated to the abnormal degradation of the p53 protein,
leading to a disruption in G1/S cell cycle control [16].
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Also, HPV-16 E7 oncoprotein binds to the phosphorylated
form of pRb protein, which inactivates pRb and a disrup-
tion in the G1/S transition occurs [17]. Both events cause
an abnormal promotion of cell proliferation due to disrup-
tions in the cell cycle control mechanisms. HPV-16 DNA
has been detected in almost 35 % of HNSCC patients, and
evidence has accumulated showing that HPV is etiologic
for OPSCC [18, 19]. It has been proposed that HPV-16
positive HNSCC patients have a distinct cancer progres-
sion and prognosis than HPV-16 negative HNSCC pa-
tients [20]. HPV-16 positive patients tend to be diagnosed
at a younger age when compared to HPV-16 negative pa-
tients [20, 21]. Additionally, the presence of HPV-16 in
HNSCC patients has been correlated to the presence of
local metastases, positive lymph nodes, and a more ad-
vanced tumor stage at the time of diagnosis [22]. Clinic-
ally, HPV-16 positive HNSCC patients have a better
prognosis than HPV-16 negative patients [11, 13, 23, 24].
The complex anatomical structure of the head and neck
area makes it very challenging for clinicians to determine
the primary site of HNSCC [25]. Detection of HNSCC in-
volves clinical and histological examinations of suspicious
tissue, but, at times, unnoticed malignant lesions remain
undetected. HNSCC tumors arising from each anatomical
site have a unique progression, epidemiology, and thera-
peutic approach. HNSCC prognostication is based on the
TNM Classification of Malignant Tumors (TNM) accord-
ing to the sub-site [26]. The TNM system is useful to de-
scribe the extent of the disease, estimate the likely
prognosis, and plan treatment. Treatment strategies rely
on TNM, possible side effects, and the patient’s prefer-
ences and overall health. Since HNSCC is often discovered
in advance stages (III and IV), the most urgent problem is
the need to identify an effective diagnostic marker for
early detection, and prediction of outcome. Therefore, the
purpose of this study was to evaluate whether addition of
HPV-16 status to the TNM staging system will help pre-
dict better the OS of HNSCC Puerto Rican patients.
Methods
Study design
This is a retrospective study where patients meeting the
following criteria were eligible for inclusion: histologically
proven squamous cell carcinoma arising from the pharynx
(hypopharynx, oropharynx), oral cavity, and larynx treated
surgically between 1993 and 2005. Fresh-frozen tumor tis-
sue was collected from all HNSCC accrued patients. Add-
itionally, genomic DNA of HNSCC patients had been
previously tested for HPV-16 status by Gp5+/6+ primer
region within the L1 gene consensus PCR [27], HPV-16
E6/E7 type-specific PCR, and E6 immunohistochemical
(IHC) staining [13, 28, 29]. The cohort consisted of 185
HNSCC and their clinicopathological parameters are
shown in Table 1. All procedures have the approval of the
University of Puerto Rico-Medical Sciences Campus IRB
(MSC-IRB Protocol 2770103). Relevant diagnostic infor-
mation including tumor site, tumor grade, and histology
were obtained from medical records and pathological
reports. Treatment of choice was surgery followed by
postoperative radiotherapy. Follow-up information was
prospectively collected from hospital, pathological records
and the Puerto Rican Cancer Registry.
DNA extraction
Genomic DNA from all tumor samples was isolated
using the DNA Isolation kit for Cells and Tissues
(Roche, Indianapolis, IN) according to the manufacturer
instructions. DNA concentration was measured with
NanoDrop 8000 UV–vis Spectrophotometer (Thermo
Scientific, Waltham, MA).
Table 1 Study cohort clinicopathological characteristics
Characteristics N = 185
Age (y)





Primary Tumor Site, n (%)
Larynx 83 (44.9)
Oral Cavity 68 (36.7)
Oropharynx 17 (9.2)
Hypopharynx 17 (9.2)
HPV-16 Status, n (%)*
HPV-16 + 97 (52.4)
HPV-16 - 88 (47.6)
Tumor Stage, n (%)
I, II 47 (25.4)
III, IV 138 (74.6)








Heavy Smoking, n (%) 163 (88.1)
Heavy Drinking, n (%) 154 (83.2)
*HPV-16 + = human papillomavirus type 16 positive; HPV-16 - = human
papillomavirus type 16 negative
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Detection of HPV16 DNA
HPV-16 status had been pre-screened by Gp5+/6+ con-
sensus PCR followed by HPV-16 E6/E7 type-specific
PCR, and results were confirmed for this study with a
TaqMan-based qPCR targeted at HPV-16 E6 and E7
viral oncogenes. The HPV-16 E6 specific primer set in-
cluded a forward primer 5′-gcacagagctgcaaacaactataca-3′,
a reverse primer 5′-tcccgaaaagcaaagtcatatacc-3′, and
a probe oligo 5′-tgtactgcaagcaacagttactgcgacgt-3′.
The HPV-16 E7 specific primer set included a forward
primer 5′-gatgaaatagatggtccagc-3′, a reverse primer
5′-gctttgtacgcaaccgaagc-3′, and a probe oligo 5′-cggac
agagcccattacaatattgtaacc-3′. Quality and amount of in-
put DNA samples were tested in each qPCR assay
with β-actin gene primers with a forward primer 5′-gc
ccatctacgaggggta-3′, a reverse primer 5′-ccttaatgtcacgc
acga-3′, and a probe oligo 5′-accaccacggccgagcgg-3′. Re-
action mixtures with SiHa DNA (1–2 copies of HPV-16)
and K562 DNA (HPV-16 negative) were used as positive
and negative control, respectively. qPCR reactions were
carried out in a 96-well optical tray with a final volume of
25 μL. Each reaction consisted of 600 nM of each primer,
200 nM of each probe (Taqman, Applied Biosystems,
Grand Island, NY), 1X of TaqMan Universal PCR Master
Mix (Applied Biosystems), which contains the Taq Poly-
merase, dNTPs, and ROX reference dye, and 75 ng of
genomic DNA. DNA was amplified in a 7500 Real Time
PCR System (Applied Biosystems, Grand Island, NY).
Thermal cycling conditions were: 50 °C for 2 min, 95 °C
for 10 min, followed by 40 cycles of 95 °C for 15 s and an
annealing temperature of 60 °C for 1 min. All HNSCC
samples classified as HPV-16 positive had amplification of
E6 and E7 viral oncogenes through qPCR assay.
Statistical analysis
Data from independent groups was compared using Fisher
exact test or x2, as appropriate. Odds ratio (OR) calculations
for clinicopathological parameters were performed using
binary logistic. Overall survival (OS) was measured in
months from the date of diagnosis until death, if occurred.
Survival analyses were performed using Kaplan-Meier
curves. Log-rank Mantel-Cox and Gehan-Breslow Wilcoxon
tests were used to determine the significance between two
survival curves. Established prognostic factors having an im-
pact on HNSCC survival were analyzed in a multivariate
Cox regression analysis. Statistical significance was estab-
lished to be p ≤ 0.05. Statistical analyses were performed
using IBM SPSS Version 22 (IBM Corp; Armonk, NY).
Results
HPV-16 status in a cohort of HNSCC Puerto Rican patients
Patient characteristics are shown in Table 1. The mean
age was 62.72 years (range 24–98 SD: 12.13). Of the 185
HNSCC patients included in the study, 88.6 % were male
and 11.4 % were female. Three-quarters (74.6 %) of the pa-
tients presented tumors with advance staging (III and IV)
and 25.4 % were in early stages (I and II) of the disease.
The HNSCC sub-site distribution was 44.9 % LSCC,
36.7 % OSCC and 18.4 % PSCC. The PSCC sub-site in-
cludes cases from the oropharynx and hypopharynx. Pa-
tients with oropharyngeal and hypopharyngeal cancers
were combined under PSCC for the statistical analysis in
view of the relatively small number of cases of each sub-
site in our study cohort. However, the distribution of
oropharyngeal and hypopharyngeal cancers is shown in
Table 1. Smoking and drinking habits of our study cohort
Table 2 Adjusted OR’s and 95 % CIs of HNSCC patients





OR value, 95 % CI P value
No. Percent No. Percent
Age (y)
≤ 60 45 46.4 38 43.2
> 60 52 53.6 50 56.8 1.14 [0.637 – 2.035] 0.767
Sex
Male 89 91.8 75 85.2
Female 8 8.2 13 14.8 1.93 [0.759 – 4.902] 0.173
Tumor site
Larynx 41 42.3 42 47.7 0.866 [0.304 – 2.470] 0.788
Oral
Cavity
36 37.1 32 36.4 0.998 [0.338 – 2.942] 0.996
Pharynx 20 20.6 14 15.9 1.675 [0.420 – 6.681] 0.465
Stage of Disease
I,II 30 30.9 17 19.3
III,IV 67 69.1 71 80.7 1.87 [0.945 – 3.700] 0.091
Tumor grade
SCC 11 11.3 8 9.1
Well 22 22.7 21 23.9 0.875 [0.226 – 3.385] 0.847
Moderate 55 56.7 52 59.1 0.729 [0.269 – 1.973] 0.534
Poor 9 9.3 7 7.9 0.720 [0.240 – 2.161] 0.558
Nodal involvement
Yes 30 16.2 34 18.4
No 67 36.2 54 29.2 0.711 [0.387-1.306] 0.272
Tobacco status
Yes 88 90.7 75 85.2
No 9 9.3 13 14.8 1.70 [0.686 – 4.186] 0.265
Alcohol status
Yes 82 84.5 72 81.8
No 15 15.5 16 18.2 1.22 [0.561 – 2.630] 0.695
HPV-16 + human papillomavirus type 16 positive, HPV-16 - human
papillomavirus type 16 negative, OR odds ratio, 95 % CI 95 %
confidence interval
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were defined according to the substance usage reported
by each consented patient. Heavy smoking patients re-
ported smoking a pack or more of cigarettes per day and
heavy drinking patients reported 15 drinks or more per
week. The majority of our HNSCC patients were heavy
smokers (88.1 %) and heavy drinkers (83.2 %).
When we distribute the study cohort by HPV-16
status, 52.4 % were HPV-16 positive and 47.6 % were
HPV-16 negative. The HNSCC sub-site distribution of
the HPV-16 positive patients was 42.3 % LSCC, 37.1 %
were OSCC and 20.6 % were PSCC. No statistically signifi-
cant association was found between HPV-16 status and
gender, age, risk factors and staging (Table 2).
Survival analysis of HNSCC patients according to
HPV-16 status
HNSCC patients with HPV-16 positive status had a bet-
ter OS compared to HPV-16 negative patients for all
sites and stages (Fig. 1). HPV-16 positive patients had a
median survival of 102.8 months compared to HPV-16
negative tumors, which had a 63.1 months median sur-
vival (P = 0.002). Cox regression analysis was performed
and showed that HPV-16 positive HNSCC patients have
an improved survival compared to HPV-16 negative pa-
tients after adjustment for established prognostic factors
such as nodal status, tumor stage, cell differentiation,
tumor site, heavy smoking and heavy drinking usage,
age, and sex (Table 3).
LSCC and PSCC patients with HPV-16 positive tumors
had a better OS compared to HPV-16 negative patients
(Fig. 2a, 2b). The median survival of HPV-16 positive LSCC
patients was 118 months compared to HPV-16 negative
cases which had a median survival of 58.1 months (P =
<0.001). As well, the OS of PSCC patients improves in
HPV-16 positive cases (129.2 months) compared to HPV-16
negative cases (20.4 months) (P= <0.001). In contrast, the
OS of OSCC patients was not significantly different between
HPV-16 positive and HPV-16 negative cases (Fig. 2c).
Since HPV-16 positive patients showed a better sur-
vival, we evaluated the effect of HPV-16 presence on OS
in HNSCC tumor staging. As shown in Fig. 3, HPV-16
positive patients have a better OS than HPV-16 negative
patients regardless of the tumor staging. HPV-16 posi-
tive early stage tumors had an improved OS of
106.8 months as compared to HPV-16 negative tumors,
which had a median OS of 63.2 months (P = 0.056)
(Fig. 3a). Likewise, late stage tumors that were HPV-16
positive had a better OS (95.2 months) compared to late
stages HPV-16 negative tumors, whose median OS was
60.1 months (P = 0.011) (Fig. 3b).
Recent studies have observed that HPV-16 positivity is
a strong prognostic marker for OS in patients treated
with primary radio-chemotherapy [30]. We compared
Fig. 1 Overall survival of HNSCC patients according to HPV-16
status. Kaplan-Meier survival curve analysis of HNSCC patients
according to HPV-16 status. Analysis includes all 185 HNSCC
patients for all anatomical sub-sites and stages
Table 3 Multivariate Cox analysis
Covariate Coefficient Standard
error
P value HR value, 95 % CI
Positive nodal
status
0.308 0.209 0.141 1.361 [0.903 – 2.052]
Tumor stage 0.034 0.099 0.733 1.034 [0.852 – 1.257]
Tumor grade
Well 0.089 0.442 0.841 1.093 [0.460 – 2.598]
Moderate 0.348 0.322 0.279 1.417 [0.754 – 2.662]
Poor 0.496 0.344 0.149 1.642 [0.837 – 3.222]
Tumor site
Larynx - 0.170 0.337 0.614 0.844 [0.436 – 1.634]
Oral Cavity - 0.176 0.350 0.616 0.839 [0.423 – 1.665]
Pharynx 0.237 0.423 0.575 1.267 [0.554 – 2.901]
Heavy smoking 0.202 0.329 0.539 1.224 [0.642 – 2.333]
Heavy drinking 0.217 0.249 0.384 1.242 [0.762 – 2.024]
HPV-16 0.555 0.182 0.002 1.742 [1.219 – 2.488]
Sex - 0.247 0.324 0.447 0.781 [0.414 – 1.475]
Age 0.026 0.007 0.000 1.026 [1.011 – 1.041]
(−2 Log Likelihood): 1051.086, HR hazard ratio, 95 % CI 95 % confidence
interval, HPV-16 human papillomavirus type 16
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the OS of HNSCC patients, of all sub-sites and tumor
stages, which were treated with radiotherapy adjuvant to
surgery. We found that HPV-16 positive patients ex-
posed to radiotherapy after surgery had an improved
survival compared to HPV-16 negative patients (Fig. 4a).
Furthermore, when we sub-divide HNSCC patients by
tumor site and radiotherapy treatment, HPV-16 positive
LSCC and PSCC patients showed a better OS than
HPV-16 negative patients (Fig. 4b, 4c). In contrast,
OSCC patients, treated with adjuvant radiotherapy, do
not show difference in OS in the presence or absence of
HPV-16 (Fig. 4d).
Fig. 2 Overall survival of HNSCC patients according to HPV-16 status in each HNSCC anatomical sub-sites. Kaplan-Meier survival curve analysis of
HPV-16 positive patients versus HPV-16 negative patients according to HNSCC anatomical sub-site. a Larynx (LSCC); b Pharynx (PSCC); c Oral Cavity (OSCC)
Fig. 3 Overall survival of HNSCC patients according to HPV-16 status and tumor staging. Kaplan-Meier survival curve analysis of HNSCC HPV-16
positive patients versus HPV-16 negative patients distributed by tumor staging. a Early Stages (I and II); b Late Stages (III and IV)
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Since our study cohort was mostly composed of heavy
smokers (88 %), we evaluated if HPV-16 status affects
the OS of a HNSCC smoker population. As shown on
Fig. 5, HPV-16 positive heavy smokers had a better OS
(104.2 months) compared to HPV-16 negative heavy
smokers (57.3 months) (P = <0.001). Likewise, the OS of
HPV-16 positive patients with a history of heavy alcohol
consumption was better (99.9 months) than HPV-16
negative patients (65.1 months) (P = 0.012) (Fig. 6).
Discussion
Our study shows that HPV-16 positivity modifies the OS of
HNSCC patients in two anatomical sub-sites, PSCC and
LSCC, but not in OSCC (Fig. 2). Previous studies have
shown that HPV-16 infection in LSCC and PSCC increased
the survival of HNSCC patients [11, 31]. In contrast, a re-
cent study shows that HPV-16 infection in OSCC does not
cause an increase in survival, supporting our findings [32].
The key mechanism for which HPV-16 infection gives
a better prognosis to HNSCC patients is still unknown.
However, it has been proposed that HPV-16 positive
cells have an increased sensitivity to cancer therapies, a
slower cellular growth rate, an enhanced immune re-
sponse towards the virus, or a combination of these fac-
tors [33]. Additionally, it has been shown that HPV-16
positive cells have fewer DNA copy number alterations,
less genome-wide hypomethylation, less TP53 mutations,
and lower expression of EGFR [34]. Because of those dif-
ferences, two HNSCC carcinogenesis models have being
proposed. The first model suggests that progression of
HNSCC, not infected by HPV-16, may be due to the
amplification or loss of large parts of chromosome arms
3p, 9p, 11p and 17p [35–37]. In contrast, the second
model of HNSCC carcinogenesis suggests that tumors
infected with HPV-16 have a lower level of chromo-
somal loss at these regions, which may be the cause for
a better survival in these patients [37].
It has been proposed that HPV-16 positivity in
HNSCC produces distinct tumor sub-site differences
when exposure risks are combined, suggesting that
Fig. 4 Overall survival of HNSCC patients exposed to radiation according to HPV-16 status and HNSCC sub-sites. Kaplan-Meier survival curve
analysis of HNSCC patients exposed to radiotherapy (RTX) adjuvant to surgery. Patients were distributed by HPV-16 status and anatomical
sub-site. a All RTX patients, which includes all HNSCC sub-sites and stages; b Larynx RTX patients; c Pharynx RTX patients; d Oral Cavity RTX patients
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different molecular pathways are involved [38]. When
we evaluated HPV-16 presence in each HNSCC ana-
tomic sub-site, we demonstrated that HPV-16 status has
a unique impact in the patient’s survival. HPV-16 posi-
tive LSCC and PSCC patients have an improved survival,
in contrast to OSCC patients which did not show an
improved survival. This difference may arise due to
smoking and drinking habits of our study population.
Our study cohort is composed of heavy smokers
(88.1 %) and heavy drinkers (83.2 %). It has been pro-
posed that HNSCC carcinogenesis in HPV-16 positive
tumors, with a history of heavy smoking, may arise upon
HPV-16 infection in pre-neoplastic tissue already having
a number of genetic alterations, for instance, p53 muta-
tions or an increase in EGFR expression [39]. If such al-
terations are acquired prior to HPV-16 infection, it may
impart some of the molecular characteristics of HPV-16
negative tumors, thus resulting in poor outcome and
prognosis [40]. Also, it has been suggested that tobacco,
alcohol and HPV-16 are independent risk factors for
HNSCC, producing distinct tumor groups with different
prognosis and guide of treatment [41].
HPV-16 status is an important factor for establishing the
prognosis and treatment of HNSCC. Our results showed
that HPV-16 positive patients had a better response to
radiotherapy when compared to HPV-16 negative patients.
This increase in radiosensitivity could be mediated through
wild–type p53-mediated apoptosis in HPV-16 positive cells
and a lower chromosomal loss [42].
The primary limitations of this study are the small num-
ber of early stages (I and II) HNSCC samples, and a small
group of PSCC’s in our study cohort. These limitations
may explain why we did not observe a statistical difference
in early stage tumors by HPV-16 status. Our HNSCC pa-
tient population is composed mostly of late stage tumors
(III, IV), predominantly from LSCC and OSCC. This issue
occurs because our head and neck cancer service is at-
tached to a supraterciary level hospital care center which
is responsible for the management of complex cancer
cases for the whole island of Puerto Rico.
Conclusions
In this study we showed that, HPV-16 presence, in
HNSCC tumors, causes an increase in OS and increases
radiosensitivity of tumor cells. Interestingly, we have
shown that HPV-16 is present, not only in OPSCC as
previously described, but it was also detected in LSCC
and OSCC. Although the TNM classification has been
effective for prognostication of HNSCC, HPV-16
Fig. 5 Overall survival of HNSCC patients with heavy smoking
history according to HPV-16 status. Kaplan-Meier survival curve
analysis of HPV-16 positive versus HPV-16 negative HNSCC patients
with a history of heavy smoking
Fig. 6 Overall survival of HNSCC patients with heavy alcohol
consumption history according to HPV-16 status. Kaplan-Meier
survival curve analysis of HPV-16 positive versus HPV-16 negative
HNSCC patients with a history of heavy alcohol consumption
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detection may serve as a potential biomarker, in combin-
ation with the TNM, to better establish the prognosis of
LSCC and PSCC and guide treatment. Future work should
be directed to understand how HPV-16 affects HNSCC
carcinogenesis, and how its infection modifies the disease
progression increasing the OS in these patients.
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